Clinical Trials
8 trialsNCT03349450 2026-05-06
SPiReL
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT06484920 2026-02-10
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
Indiana University
Phase 2 Recruiting
NCT03210662 2026-01-13
Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT07283822 2025-12-16
Amping up With PemJAK
Columbia University
Phase 2 Recruiting
NCT04827862 2025-12-05
RADVAXâ„¢ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy
Abramson Cancer Center at Penn Medicine
Phase 2 Active not recruiting
NCT03498612 2025-11-12
Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
University of Washington
Phase 2 Terminated
NCT03401853 2025-07-22
Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
University of Washington
Phase 2 Terminated
NCT03255018 2023-11-28
Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed